Enhanced Stability of the FeII/MnII State in a Synthetic Model of Heterobimetallic Cofactor Assembly

Site-Differentiated MnIIFeII Complex Reproducing the Selective Assembly of Biological Heterobimetallic Mn/Fe Cofactors

Class Ic ribonucleotide reductases (RNRIc) and R2-like ligand-binding oxidases (R2lox) are known to contain heterobimetallic Mn^IIFe^II cofactors. How these enzymes assemble Mn^IIFe^II cofactors has been a long-standing puzzle due to the weaker binding affinity of Mn^II versus Fe^II. In addition, the heterobimetallic selectivity of RNRIc and R2lox has yet to be reproduced with coordination complexes, leading to the hypothesis that RNRIc and R2lox overcome the thermodynamic preference for coordination of Fe^II over Mn^II with their carefully constructed three-dimensional protein structures. Herein, we report the selective formation of a heterobimetallic Mn^IIFe^II complex accomplished in the absence of a protein scaffold. Treatment of the ligand Py₄DMcT (L) with equimolar amounts of Fe^II and Mn^II along with two equivalents of acetate (OAc) affords [LMn^IIFe^II (OAc)₂(OTf)]⁺ (Mn^IIFe^II) in 80% yield, while the diiron complex [LFe^IIFe^II(OAc)₂(OTf)]⁺ (Fe^IIFe^II) is produced in only 8% yield. The formation of Mn^IIFe^II is favored regardless of the order of addition of Fe^II and Mn^II sources. X-ray diffraction (XRD) of single crystals of Mn^IIFe^II reveals an unsymmetrically coordinated carboxylate ligand─a primary coordination sphere feature shared by both RNRIc and R2lox that differentiates the two metal binding sites. Anomalous XRD studies confirm that Mn^IIFe^II exhibits the same site selectivity as R2lox and RNRIc, with the Fe^II (d⁶) center preferentially occupying the distorted octahedral site. We conclude that the successful assembly of Mn^IIFe^II originates from (1) Fe-deficient conditions, (2) site differentiation, and (3) the inability of ligand L to house a dimanganese complex.

Novel phenolic antimicrobials enhanced activity of iminodiacetate prodrugs against biofilm and planktonic bacteria

Prodrugs are pharmacologically attenuated derivatives of drugs that undergo bioconversion into the active compound once reaching the targeted site, thereby maximizing their efficiency. This strategy has been implemented in pharmaceuticals to overcome obstacles related to absorption, distribution, and metabolism, as well as with intracellular dyes to ensure concentration within cells. In this study, we provide the first examples of a prodrug strategy that can be applied to simple phenolic antimicrobials to increase their potency against mature biofilms. The addition of (acetoxy)methyl iminodiacetate groups increases the otherwise modest potency of simple phenols. Biofilm-forming bacteria exhibit a heightened tolerance toward antimicrobial agents, thereby accentuating the need for new antibiotics as well as those, which incorporate novel delivery strategies to enhance activity toward biofilms.

Tuning the MnII2/MnIII2 redox cycle of a phenoxo-bridged diMn catalase mimic with terminal carboxylate donors

A new phenoxo-bridged diMn^III complex, Na[Mn₂L(OH)₂(H₂O)₂]·5H₂O (1), obtained with the ligand L^5- = 5‑methyl‑2‑hydroxo‑1,3‑xylene‑α,α‑diamine‑N,N,N',N'‑tetraacetato, has been prepared and characterized. Mass spectrometry, conductivity, UV-visible, EPR and ¹H NMR spectroscopic studies showed that the complex exists in solution as a monoanionic diMn^III complex. Complex 1 catalyzes H₂O₂ disproportionation with second-order rate constant k_cat = 305(9) M^-1 min^-1 and without a time-lag phase. Based on spectroscopic results, the catalase activity of complex 1 in methanol involves a Mn^III₂/Mn^II₂ redox cycle, which distinguishes this catalyst from other phenoxo-bridged diMn complexes that cycle between Mn^IIMn^III/Mn^IIIMn^IV species. Addition of base stabilizes the catalyst, restrains demetallation during catalysis and causes moderate enhancement of catalase activity. The terminal carboxylate donors of 1 not only contribute as internal bases to assist deprotonation of H₂O₂ but also favor the formation of active homovalent diMn species, just as observed for the enzyme.

Divergent assembly mechanisms of the manganese/iron cofactors in R2lox and R2c proteins

A manganese/iron cofactor which performs multi-electron oxidative chemistry is found in two classes of ferritin-like proteins, the small subunit (R2) of class Ic ribonucleotide reductase (R2c) and the R2-like ligand-binding oxidase (R2lox). It is unclear how a heterodimeric Mn/Fe metallocofactor is assembled in these two related proteins as opposed to a homodimeric Fe/Fe cofactor, especially considering the structural similarity and proximity of the two metal-binding sites in both protein scaffolds and the similar first coordination sphere ligand preferences of Mn^II and Fe^II. Using EPR and Mössbauer spectroscopies as well as X-ray anomalous dispersion, we examined metal loading and cofactor activation of both proteins in vitro (in solution). We find divergent cofactor assembly mechanisms for the two systems. In both cases, excess Mn^II promotes heterobimetallic cofactor assembly. In the absence of Fe^II, R2c cooperatively binds Mn^II at both metal sites, whereas R2lox does not readily bind Mn^II at either site. Heterometallic cofactor assembly is favored at substoichiometric Fe^II concentrations in R2lox. Fe^II and Mn^II likely bind to the protein in a stepwise fashion, with Fe^II binding to site 2 initiating cofactor assembly. In R2c, however, heterometallic assembly is presumably achieved by the displacement of Mn^II by Fe^II at site 2. The divergent metal loading mechanisms are correlated with the putative in vivo functions of R2c and R2lox, and most likely with the intracellular Mn^II/Fe^II concentrations in the host organisms from which they were isolated.